LQDA
Liquidia Corp
NASDAQ · Pharmaceuticals
$43.04
+1.48 (+3.56%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 15.47M | 15.03M | 825.78M | 783.80M | 707.55M |
| Net Income | -144,125,417 | -126,069,467 | 159.71M | 150.56M | 137.41M |
| EPS | — | — | — | — | — |
| Profit Margin | -931.7% | -885.1% | 19.3% | 19.2% | 19.4% |
| Rev Growth | +2.9% | +2.9% | -2.7% | +0.6% | +0.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 1.12B | 1.12B | 1.23B | 962.93M | 1.24B |
| Total Equity | 750.81M | 750.81M | 1.18B | 1.27B | 1.28B |
| D/E Ratio | 1.49 | 1.49 | 1.04 | 0.76 | 0.97 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -138,688,199 | -128,053,055 | 249.33M | 266.89M | 249.48M |
| Free Cash Flow | — | — | 104.32M | 76.52M | 82.10M |